LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Home・Lista de Ações・AnaptysBio Inc

AnaptysBio Inc

Fechado

SetorSaúde

51.39 1.86

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

49.8

Máximo

52.53

Indicadores-chave
By Trading Economics
Rendimento	-102M -53M
Vendas	-83M 26M
EPS	-1.843
Margem de lucro	-206.934
Funcionários	104
EBITDA	-102M -34M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+43.93% upside

Dividendos
By Dow Jones
Próximos Ganhos	4 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-430M 1.5B
Abertura anterior	49.53
Fecho anterior	51.39

Sentimento de Notícias

By Acuity

93%

319 / 344 Ranking em Healthcare

AnaptysBio Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

8 de jun. de 2026, 22:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 de jun. de 2026, 15:41 UTC

Grandes Movimentos do Mercado

American Battery Shares Jump on Energy Department Victory

8 de jun. de 2026, 23:46 UTC

Conversa de Mercado

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 de jun. de 2026, 23:37 UTC

Conversa de Mercado

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 de jun. de 2026, 23:25 UTC

Conversa de Mercado

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 de jun. de 2026, 23:25 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

8 de jun. de 2026, 21:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 de jun. de 2026, 21:56 UTC

Aquisições, Fusões, Aquisições de Empresas

Salesforce Agrees to Buy m3ter

8 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

8 de jun. de 2026, 19:22 UTC

Conversa de Mercado

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 de jun. de 2026, 19:01 UTC

Conversa de Mercado

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 de jun. de 2026, 18:52 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

8 de jun. de 2026, 18:52 UTC

Conversa de Mercado

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 de jun. de 2026, 18:17 UTC

Conversa de Mercado

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 de jun. de 2026, 17:32 UTC

Conversa de Mercado

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 de jun. de 2026, 17:29 UTC

Conversa de Mercado

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 de jun. de 2026, 17:29 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 de jun. de 2026, 16:55 UTC

Aquisições, Fusões, Aquisições de Empresas

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 de jun. de 2026, 16:54 UTC

Aquisições, Fusões, Aquisições de Empresas

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 de jun. de 2026, 16:40 UTC

Conversa de Mercado

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 de jun. de 2026, 16:31 UTC

Conversa de Mercado

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 de jun. de 2026, 16:27 UTC

Conversa de Mercado

Mexican Inflation Seen Easing in May -- Market Talk

8 de jun. de 2026, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

8 de jun. de 2026, 16:03 UTC

Aquisições, Fusões, Aquisições de Empresas

Orange Bought Stake From Lorca

8 de jun. de 2026, 16:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 de jun. de 2026, 16:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Orange Acquires 100% Ownership of MasOrange

8 de jun. de 2026, 15:58 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

8 de jun. de 2026, 15:58 UTC

Conversa de Mercado

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 de jun. de 2026, 15:55 UTC

Conversa de Mercado

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 de jun. de 2026, 15:41 UTC

Conversa de Mercado

Gold Falls Below 200-Day Moving Average -- Market Talk

Comparação entre Pares

Variação de preço

AnaptysBio Inc Previsão

Preço-alvo

By TipRanks

43.93% parte superior

Previsão para 12 meses

Média 72.5 USD 43.93%

Máximo 93 USD

Mínimo 50 USD

Com base em 9 analistas de Wall Street que oferecem metas de preço de 12 meses para AnaptysBio Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

9 ratings

Comprar

Manter

Vender

Com base em 9 analistas que deram avaliações de ações para AnaptysBio Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

319 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.